(via TheNewswire)
![]() | |||||||||
![]() | ![]() | ![]() | ![]() | ![]() |
“During the first quarter we focused on effecting leadership change in the company and assessing the status of the technology, user base, operations and commercialisation. The Ventripoint team worked closely with our EU and
“We remain committed to enhancing the level of care provided to the 13 million worldwide sufferers of congenital heart defects with affordable, accurate and reliable measurements of heart structure and function and intend to establish market leadership by 2025. Concurrently the Company is actively identifying additional clinical indications and market segments in which VMS+ offers a clear value proposition.”
Highlights include:
Sale of a second unit to
Duke University Hospital Migration of the corporate website to a new platform
Sponsorship of the AEPC conference in
Porto, Portugal and delivery of two hands-on workshops with VMS+Submission of VMS+ V4.0 to FDA for 510(k) clearance
Recruitment of two members to the marketing team
Annual MDSAP audit
Regulatory approval of VMS+ in
New Zealand Selection of a regulatory consultant for
Brazil Initiation of financing of up to
$3M CAD through convertible debentures
In other news,the Company’s financial results for the first quarter ended
The Company wishes to invite its shareholders to a teleconference to be held on
• Participants can access the call by dialing 1-844-763-8274 or +1-647-484-8814. It is recommended that you call 10 minutes before the scheduled start time to avoid the queue.
• After the call, an audio recording will be made available via telephone for one month, until end of day
• A written transcript of the call will be available on Ventripoint’s website shortly after its conclusion.Forfurther information, please contact:
JRobinson@oakhillfinancial.ca
416-669-1001
Neither the
ForwardLooking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR atwww.sedar.com.Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws
Copyright (c) 2024 TheNewswire - All rights reserved.
Copyright (c) 2024 TheNewswire - All rights reserved., source